

REMARKS

Applicants thank Examiner Epperson for speaking with Diane M. Tsuda, by phone on September 28, 2004. Claims 1-13, 15-20, and 22-26 were pending prior to this response. By the present communication, claims 2, 13, 15, 18, and 26 have been cancelled without prejudice, no claims have been added, and claims 1, 10, 16, and 19 have been amended to define Applicants' invention with greater particularity. The claim amendments add no new matter, being fully supported by the Specification and original claims. Accordingly, claims 1, 3-12, 16, 17, 19, 20, and 22-25 are currently pending.

The Rejection Under 35 U.S.C. § 112, First Paragraph

Applicants respectfully traverse the rejection of claims 1-13, 15-20, and 22-26 under 35 U.S.C. § 112, first paragraph, for allegedly lacking description commensurate with the scope of the claims, as applied to the currently pending claims. Applicants disagree with the Examiner's application of *Univ. of Rochester v G.D. Searle & Co., Inc.*, 358 USPQ2d 1886 (Fed. Cir. 2004) to the present claims. In the *Univ. of Rochester* case, the Applicants were claiming a compound that interacted with a particular chemical entity, namely PGHS-2. Presumably, a class of compounds having certain structural characteristics in common would be required. By contrast, in the present invention claim 1 describes "a method for identifying a polynucleotide encoding a enzyme of interest", but does not require that the polynucleotide encoding the enzyme of interest have any other property than its ability to hybridize to a probe polynucleotide that has been preselected by the practioner as containing a probe-length portion of a DNA sequence that encodes "an enzyme of interest". The user is free to select "the enzyme of interest," but the target in this case is unknown and cannot be described chemically other than by its hybridization with the probe molecule. Thus there is a fundamental difference between the claims of the *Univ. of Rochester* case and the claims at issue here.

No description of the atoms making up either the probe molecule or the enzyme of interest needs to be provided, or can be provided, and Applicants respectfully submit that those

of skill in the art would understand that the chemical interaction known in the art as “hybridization” is a specific description of a chemical phenomenon.

Therefore, it appears that the Examiner is interpreting the “written description requirement” as requiring that the claim be narrowed in an inappropriate manner. The invention methods, as defined by amended claim 1, do not require one skilled in the art to arrive at any particular chemical entity that could be described in terms of the atomic makeup or chemical structure. All that is required, is hybridization of a polynucleotide to a complementary segment in a probe bearing a detectable label. Moreover, the “common attribute” that functions in the invention claims is hybridization of complementary DNA sequences, which (under such conditions and for such time as to allow hybridization of complementary sequences, *as required in claim 1*) is a universal chemical phenomenon and not unpredictable, despite the Examiner’s assertion to the contrary.

What is “common” and predictable in all DNA hybridization reactions under suitable conditions is that A binds to T and C binds to G, just the same as oxygen binds to hydrogen under suitable conditions. Thus, complementary sequences under the right conditions inevitably bind to one another and the chemical laws governing such a phenomenon do not differ according to whether the DNA sequence from which the probe is constructed encodes one or a different type of enzyme. If an analogy to chemical interactions between specific atoms or combinations is required, Applicants submit that A, T, C and G are specific, commonly known chemical constructs and the binding affinity of complementary strands of DNA is so well known in the art that an Applicant is not required to meet the “heightened” written description requirement of Section 112, first paragraph.

Thus, Applicants submit that the Examiner’s demand for application of the “heightened” written description requirement appropriate to an unpredictable art area (Office Action, page 6) is inapposite as applied to the present claims. In view of the universal applicability and predictability of the chemistry involved, and the total absence of any *claim* to discovery of a particular chemical construct or particular type of enzymatic activity, applicants respectfully

submit that the description of the invention clearly allows persons of ordinary skill in the art to recognize the that [the inventors] invented what is *claimed* as required by *In re Gosteli* (872 F.2d 1008,1012, 10 USPQ2d 1614 (Fed. Cir. 1989).

To further prosecution of this application, Applicants have amended claim 1 to recite “A method for identifying an enzyme of interest, comprising: (a) obtaining a plurality of polynucleotides derived from a mixed population of organisms or more than one organism; (b) normalizing the representation of organisms present in the plurality of polynucleotides to increase representation of rare species; (c) contacting a library containing clones of normalized polynucleotides from (b) with at least one oligonucleotide probe labeled with a detectable molecule, wherein the probe comprises at least a portion of a polynucleotide sequence encoding an enzyme of interest; (d) incubating the clones under such conditions and for such time as to allow hybridization of complementary sequences; (e) separating clones with an analyzer that detects the detectable molecule; (f) contacting the separated clones with a reporter system that comprises a substrate for the enzyme of interest; and (g) identifying clones capable of modulating expression or activity of the reporter system thereby identifying a polynucleotide that encodes the enzyme of interest.” The amended language has been narrowed to recite an enzyme, a more clearly described probe, and conditions for identifying clones. Support for the amended claim language may be found in the Specification at page 34, lines 1-5; page 17, lines 14-18 and lines 21-29.

Therefore, Applicants respectfully submit that claim 1 and those dependent thereon, as presently amended, meet the requirements of “written description” under 35 U.S.C. § 112, first paragraph. Accordingly, reconsideration and withdrawal of the rejection are respectfully requested.

The Rejection Under 35 U.S.C. § 112, Second Paragraph

Applicants respectfully traverse the rejection of claim 22 under 35 U.S.C. § 112, second paragraph, as allegedly being indefinite.

With regard to claim 22, the Examiner alleges that the phrase “small molecule” is a relative term, thus introducing lack of clarity into the claim. However, Applicants submit that the phrase “small molecule” as used in Applicants’ specification and claims does not refer specifically to the size of the molecule. Despite the Examiner’s assertion that the broadest dictionary definition of the term “small” should prevail, Applicants submit that such an interpretation is “unreasonable” and thus in contravention of the rules covering definiteness, which hold that a dictionary definition does not necessarily apply when a term is used as a term of art. Applicants submit that those of skill in the art would understand “small” in the phrase “small molecule” as belonging to a term of art that distinguishes, for example, between enzymatic chemical compounds, and enzymatic polypeptides.

Not only is the phrase “small molecule” used as a term of art in the Specification and in claim 22, it would be understood by those of skill in the art to be correctly used. Thus, Applicants disagree with the Examiner’s assertion that Applicants “acting as their own lexicographers” have given the term “small” in the phrase “small molecule” a meaning that is “repugnant to the usual meaning of that term” (Office Action, transition from page 8 to page 9). Moreover, Applicants respectfully submit that, because the term “small molecule” has been used in the Specification as a term of art (as is “hybridize” and “hybridization”), there is no requirement for Applicants to provide a detailed explanation of the phrase that distinguishes between the dictionary meaning of the term “small” in a general context, and the meaning of the term when used in a phrase (“small molecule”) that is as a term of art. (See the Specification at page 43, lines 4-18; page 45, lines 4-9; page 76, lines 31-32.)

Accordingly, Applicants respectfully submit that those of skill in the art would readily understand the meaning of the phrase “small molecule” as used in claim 22, and respectfully request reconsideration and withdrawal of the rejection of claim 19 under 35 U.S.C. § 112, second paragraph.

The Rejection Under 35 U.S.C. § 102 (e)

Applicants respectfully traverse the rejection of claims 1-10, 13, 15-20 and 22-26 under 35 U.S.C. § 102 (e) as allegedly being anticipated by Thompson et al. (U.S. Patent No. 5,824,485; hereinafter "Thompson"). Claims 2, 13, 15, 18 and 26 have been cancelled without prejudice, thereby rendering the rejection moot as to these claims. Therefore, Applicants will address the rejection as to the currently presented claims.

Applicants respectfully submit that the invention methods for identifying an enzyme of interest, as defined by amended claim 1, distinguish over the disclosure of Thompson by requiring:

- (a) obtaining a plurality of polynucleotides derived from a mixed population of organisms or more than one organism;
- (b) normalizing the plurality of polynucleotides to allow equal representation of all polynucleotides in the mixed population of organisms;
- (c) contacting a library containing clones of normalized polynucleotides from (b) with at least one oligonucleotide probe labeled with a detectable molecule, wherein the probe comprises at least a portion of a polynucleotide sequence encoding an enzyme of interest;
- (d) incubating the clones under such conditions and for such time as to allow hybridization of complementary sequences;
- (e) separating clones with an analyzer that detects the detectable molecule;
- (f) contacting the separated clones with a reporter system that comprises a substrate for the enzyme of interest; and
- (g) identifying clones capable of modulating expression or activity of the reporter system thereby identifying a polynucleotide that encodes the enzyme of interest.

Applicants describe the effect of "normalizing" the sample of polynucleotides in the present application as follows:

[A] normalization of the environmental DNA present in these samples could allow more equal representation of the DNA from all of the species present in the original sample. This can dramatically increase the efficiency of finding interesting genes from minor constituents of the sample which may be under-represented by several orders of magnitude compared to the dominant species. (Specification, p. 20, lines 25-29)

It is clear that due to use of the terms “minor constituents” and “several orders of magnitude compared to the dominant species” normalization refers to changing (i.e., equalizing) the abundance of DNA representative of the various species in the sample. The techniques of normalization disclosed by Applicants in the Specification produce “peaks representing the DNA from the organisms present in an environmental sample.” Obtaining equal amounts of DNA from each peak thus equalizes the representation of all nucleic acid molecules in a sample, to form a normalized library, which is then screened for a desired bioactivity (Specification, Example 2, pages 106-7). Applicants also submit that this is a genomic method. To clarify the meaning of the term “normalizing” as used in claims 1 and 3, Applicants have amended both claims to recite “normalizing the polynucleotides ... to allow equal representation of all polynucleotides in the environmental sample” and “normalizing polynucleotides obtained from a mixed population of organisms to allow equal representation of all of the species present therein” respectively. It is also important to note that the methods of the present invention are directed to the abundance of DNA, not copy number of clones.

To clarify the meaning of the term “normalizing” as used in claim 1, Applicants have amended the claim to recite “normalizing the plurality of polynucleotides to allow equal representation of all polynucleotides in the mixed population of organisms.” It is also important to note that the methods of the present invention are directed to the abundance of DNA, not copy number of clones.

Thompson is silent regarding “normalizing” environmental DNA to allow equal representation of polypeptides from all species present in a library assembled from a sample including a mixed population of organisms, as is required by Applicants’ claims. Applicants disagree with the assertion in the office action stating that Thompson discloses “normalizing the

plurality of polynucleotides,” and citing Thompson col. 32, lines 14-16. Applicants respectfully direct the Examiner’s attention to the sentence in full-context. Thompson states, “More than one initial library may be *pre-screened*, and DNA from *all the positive clones can be pooled* and used for making the biased combinatorial library.” (Col. 32, lines 13-16) Thompson goes further to state that, “*Instead of using only the total pooled genomic DNA or cDNA* of the donor organism(s), this approach will *reduce the number of clones that need to be screened* and increase the percentage of clones that will produce compounds of interest. The *preselected* fragments of DNA contain genes encoding partial or complete biosynthetic pathways, and may be *preselected by hybridizing to an initial DNA library* a plurality of probes *prepared from known genes* that may be related to or are involved in producing compounds of interest.” (Col. 31, line 65- Col. 32 line 7) Further, Thompson states: “The remaining DNA is thus *biased toward coding regions* that encode proteins involved in secondary metabolism” (Col. 32, lines 54-56) (*Emphasis added*).

As evidence of Thompson’s alleged disclosure of normalizing, the Examiner asserts that Thompson is “‘equalizing’ slow growing members in a mixed population” and repairing damaged DNA to “equalize” the numbers of the damaged polynucleotides in the sample (Office Action, page 17). However, Thompson does not use the term “equalize” in connection with such activities and, in fact, Applicants disagree that such techniques would result in “increasing the representation of rare species in the sample.” Thompson’s repair of damaged DNA or cloning of uncultured organisms to avoid prejudice to slow growing species would, in both cases, tend to restore the natural distribution of polypeptides of various species in the sample because Thompson does not disclose that only rare polynucleotides would be need to be repaired or would be slow growing. For example, over-represented species are just as likely to have damaged DNA as underrepresented species. In short, Thompson fails to disclose any procedure by which the complexity of the DNA population obtained for the library is analyzed and treated in such a way that equal representation of all species in the mixed population is in the library.

To reduce the number of *clones* that need to be screened, Thompson describes pre-selection of DNA fragments for the screening library using probes and refers to this process as

“biasing” a library. Such probes are described as being “prepared from known genes that may be related to or are involved in producing compounds of interest” (Thompson, Col 32, lines 6-7). However, rather than using the probes for screening (e.g., identifying molecules having a nucleotide sequence complementary to the probes) of a library of already “normalized” naturally occurring DNA molecules, as in Applicants’ claim 1, Thompson uses the activity probe concept for pre-screening, pre-selecting and preparing “chimeric” and “biased” *combinatorial expression libraries*” (See Thompson, Section 5.1.6.) prior to screening.

Applicants respectfully submit that the dictionary definition of “normalization” applied by the Examiner as “to cause to conform to a norm or standard” is improperly applied to the claims at issue because “normalization” in the context of the present claims is “a term of art” and those of skill in the art would understand “normalization” as a term of art and not as having the common dictionary meaning applied by the Examiner.

For example, “normalizing” and the advantages of libraries that are “normalized” are described in U.S. Patent 6,174,673 (hereinafter “the ‘673 patent”), which is incorporated by reference into the present application:

One embodiment for forming a normalized library from an environmental sample begins with the isolation of nucleic acid from the sample. This nucleic acid can then be fractionated prior to normalization to increase the chances of cloning DNA from minor species from the pool of organisms sampled. DNA can be fractionated using a density centrifugation technique, such as a cesium-chloride gradient. When an intercalating agent, such as bis-benzimide is employed to change the buoyant density of the nucleic acid, gradients will fractionate the DNA based on relative base content. Nucleic acid from multiple organisms can be separated in this manner, and this technique can be used to fractionate complex mixtures of genomes. This can be of particular value when working with complex environmental samples... This “normalization” approach reduces the redundancy of clones from abundant species and increases the representation of clones from rare species. These normalized libraries allow for greater screening efficiency resulting in the identification of cells encoding novel biological catalysts.

The ‘673 patent, incorporated by reference in the instant application, also teaches: “single-stranded nucleic acid representing an enrichment of rare sequences is amplified using

techniques well known in the art, such as polymerase chain reaction (Bames, 1994), and used to generate gene libraries. This procedure leads to the amplification of rare or low abundance nucleic acid molecules, which are then used to generate a gene library which can be screened for a desired bioactivity.”

In further support of the Applicants’ arguments regarding “normalization” as a term of art, copies of Soares et al., “Construction and characterization of a normalized cDNA library,” *Proc. Natl. Acad. Sci. USA*, Vol. 91, pp. 9228-9232, September 1994 Biochemistry (Exhibit A, attached hereto) and Sambrook et al., *Molecular Cloning: A Laboratory Manual*, 2nd edition, Cold Spring Harbor Laboratory Press, 1989, pp. 8.6-8.10 (Exhibit B, attached hereto), have been provided for the Examiner’s convenience.

In addition, Applicants question the point of the Examiner’s statement that the use of “comprising” language in the claims does not limit the “order” in which the method steps are to be carried out. Applicants respectfully submit that the claim language prescribes normalization of the polynucleotides prior to formation of the library. For example, claim 1 recites: “contacting a library containing clones of normalized polynucleotides from (b) with at least one oligonucleotide probe labeled with a detectable molecule, wherein the probe comprises at least a portion of a polynucleotide sequence encoding an enzyme of interest.” Thus, the claim language already requires the polynucleotides to be normalized before the library of clones is prepared and “contacted”.

In addition, Thompson’s omission of a “normalizing step” as the term is understood in the art makes the order of the steps in the claim irrelevant. To establish anticipation under 35 U.S.C. § 102 (e) each and every element of the claimed invention must be disclosed by a single reference. As such, Thompson fails to disclose each and every element of claim 1 (and claims dependent thereon) as would be required to establish anticipation under 35 U.S.C. 102(b). Therefore, reconsideration and withdrawal of the rejection over Thompson are respectfully requested.

The Rejection under 35 U.S.C. § 103

To establish a *prima facie* case of obviousness, three basic criteria must be met. First, there must be some suggestion or motivation, either in the references themselves or in the knowledge generally available to one of ordinary skill in the art, to modify the reference or to combine reference teachings. Second, there must be a reasonable expectation of success. Finally, the prior art reference (or references when combined) must teach or suggest all of the claim limitations. The teaching or suggestion to make the claimed combination and the reasonable expectation of success must both be found in the prior art, and not based on applicant's disclosure. *In re Vaeck*, 947 F.2d 488, 20 USPQ2d 1438 (Fed. Cir. 1991). The mere fact that references can be combined or modified does not render the resultant combination obvious unless the prior art also suggests the desirability of the combination. *In re Mills*, 916 F.2d 680, 16 USPQ2d 1430 (Fed. Cir. 1990).

Applicants respectfully traverse the rejection of claims 1-10, 13, 15-20, and 22-26 under 35 U.S.C. § 103 as allegedly being unpatentable over Thompson (as above) and Miao et al, Biotechnology and Bioengineering (1993) 42:708-715, hereinafter "Miao". Claims 2, 13, 15, 18 and 26 have been cancelled without prejudice, thereby rendering the rejection moot as to these claims. Therefore, Applicants will address the rejection as to the currently presented claims.

Applicants respectfully submit that the invention methods for identifying an enzyme of interest, as defined by amended claim 1, distinguish over the combined disclosures of Thompson and Miao by requiring:

- (a) obtaining a plurality of polynucleotides derived from a mixed population of organisms or more than one organism;
- (b) normalizing the plurality of polynucleotides to allow equal representation of all polynucleotides in the mixed population of organisms;
- (c) contacting a library containing clones of normalized polynucleotides from (b) with at least one oligonucleotide probe labeled with a detectable molecule, wherein the probe comprises at least a portion of a polynucleotide sequence encoding an enzyme of

interest;

- (d) incubating the clones under such conditions and for such time as to allow hybridization of complementary sequences;
- (e) separating clones with an analyzer that detects the detectable molecule;
- (f) contacting the separated clones with a reporter system that comprises a substrate for the enzyme of interest; and
- (g) identifying clones capable of modulating expression or activity of the reporter system thereby identifying a polynucleotide that encodes the enzyme of interest.

The discussion above regarding the deficiencies of Thompson apply equally and are incorporated here. In addition, Applicants submit that Thompson fails to suggest the invention methods, as recited by amended claim 1, because Thompson fails to disclose or suggest normalizing the polynucleotides obtained from the mixed population to equalize the representation of all species prior to placement of the polynucleotides into clones and formation of the library to increase the chances of discovering an enzyme from an organism whose presence in the original sample is rare. Instead Thompson discusses repair of damaged DNA and methods for avoiding bias to slow growing members in a mixed population, either of which may as easily restore the original distribution of organisms in the sample as not, as Applicants have discussed above. Therefore, Applicants respectfully submit that Thompson would not motivate those of skill in the art to modify Thompson to arrive at the present invention methods because Thompson's comments regarding preparation of "activity biased" libraries would not motivate those of skill in the art to normalize the library by equalizing the representation of all organisms so that the chances of discovering an activity produced by a rare organism are increased. Indeed, Thompson's activity biasing of the library may well increase the chances that screening *will not* yield an enzyme, or other activity, produced by a rare organism because the commonest species in the sample may be selected by the activity probe and therefore have increased overrepresentation in Thompson's "biased" screening library as compared with the sample.

Applicants submit that the disclosure of Miao fails to remedy the deficiencies of Thompson under 35 U.S.C. § 103. Miao's disclosure pertains to use of C12FDG as a fluorescent substrate in FACS screening of single bacterial cells of one species (i.e., *E. coli*). Thus, like Thompson, Miao is completely silent regarding screening of a *normalized* library prepared by treating the polynucleotides obtained from a mixed population to equalize the representations of all species in the original sample. Indeed, since Miao's disclosure does not pertain to screening of a plurality of species at all, as would be inherent in a "mixed population", Applicants submit that the combined disclosures of Thompson and Miao would be insufficient to motivate those of skill in the art to modify Thompson so as to yield the present invention.

In addition, even if those of skill in the art were motivated by the combined disclosures of Thompson and Miao to arrive at the invention methods, Applicants submit that the cited art would fail to provide the reasonable expectation of success that is required to show unpatentability under 35 U.S.C. § 103. Because both Thompson and Miao fail to discuss any technique by which a diverse library can be adjusted to equalize the representation of all polynucleotides obtained from a mixed population of organisms, those of skill in the art would not be justified in assuming success in the outcome of any technique that might be devised.

Accordingly, Applicants respectfully submit that the combined disclosures of Thompson and Miao, including Miao's disclosure regarding rapid screening using C12FDG, are not sufficient to teach or suggest the invention methods of amended claim 1. Thus, Applicants respectfully submit that the pending claims are not *prima facie* obvious over Thompson, nor the combined disclosures of Thompson and Miao. Accordingly, reconsideration and withdrawal of the rejection under 35 U.S.C. § 103 are respectfully requested.

In re Application of:
Short and Keller
Application No.: 09/685,432
Filed: October 10, 2000
Page 18

PATENT
Attorney Docket No.: DIVER1280-3

CONCLUSION

In summary, in view of the amendments and for the reasons set forth herein, Applicants respectfully submit that claims 1, 3-12, 16, 17, 19, 20, and 22-25 clearly and patentably define the invention and allowance of the claims is respectfully requested. If the Examiner would like to discuss any issues raised in the Office Action, the Examiner is encouraged to call the undersigned so that a prompt disposition of this application can be achieved.

Enclosed is Check No. 568727 totaling \$885.00; to cover the fees for the Request for Continued Examination (\$395) and Petition for Three-Month Extension of Time (\$490). However, the Commissioner is hereby authorized to charge any additional other fees associated with the filing submitted herewith, or credit any overpayments to Deposit Account No. 50-1355.

Respectfully submitted,

Dated: October 28, 2004



Lisa A. Haile, J.D., Ph.D.
Registration No. 38,347
Telephone: 858-677-1456
Facsimile: 858-677-1465

GRAY CARY WARE & FREIDENRICH LLP
4365 Executive Drive, Suite 1100
San Diego, CA 92121-2133
USPTO CUSTOMER NUMBER 28213

Enclosures: Exhibit A
Exhibit B

Construction and characterization of a normalized cDNA library

(brain mRNA/DNA circles/reassociation kinetics)

MARCELO BENTO SOARES*†, MARIA DE FATIMA BONALDO*†, PIERRE JELENE*†, LONG SU*†, LEE LAWTON*†, AND ARGIRIS EFSTRATIADIS†

Departments of *Psychiatry and †Genetics and Development, Columbia University, and ‡The New York State Psychiatric Institute, 722 West 168th Street, New York, NY 10032

Communicated by Isidore S. Edelman, June 8, 1994

ABSTRACT We have developed a simple procedure based on reassociation kinetics that can reduce effectively the high variation in abundance among the clones of a cDNA library that represent individual mRNA species. For this normalization, we used as a model system a library of human infant brain cDNAs that were cloned directionally into a phagemid vector and, thus, could be easily converted into single-stranded circles. After controlled primer extension to synthesize a short complementary strand on each circular template, melting and reannealing of the partial duplexes at relatively low C_0t , and hydroxyapatite column chromatography, unreassociated circles were recovered from the flow through fraction and electroporated into bacteria, to propagate a normalized library without a requirement for subcloning steps. An evaluation of the extent of normalization has indicated that, from an extreme range of abundance of 4 orders of magnitude in the original library, the frequency of occurrence of any clone examined in the normalized library was brought within the narrow range of only 1 order of magnitude.

The mRNAs of a typical somatic cell are distributed in three frequency classes (1, 2) that are presumably maintained in representative cDNA libraries. The classes at the two extremes (ca. 10% and 40–45% of the total, respectively) include members occurring at vastly different relative frequencies. On average, the most prevalent class consists of about 10 mRNA species, each represented by 5000 copies per cell, whereas the class of high complexity comprises 15,000 different species each represented by 1–15 copies only. Rare mRNAs are even more under represented in the brain, a tissue exhibiting an exceptionally high sequence complexity of transcripts (3–5).

Although even the rarest mRNA sequence from any tissue is likely to be represented in a cDNA library of 10^7 recombinants, its identification is very difficult (its frequency of occurrence may be as low as 2×10^{-6} on average or even 10^{-7} for complex tissues such as the brain). Thus, for a variety of purposes, it is advantageous to apply a normalization procedure and bring the frequency of each clone in a cDNA library within a narrow range (generation of a perfectly equimolar cDNA library is practically impossible in our experience). Normalized cDNA libraries can facilitate positional cloning projects aiming at the identification of disease genes, can increase the efficiency of subtractive hybridization procedures, and can significantly facilitate genomic research pursuing chromosomal assignment of expressed sequences and their localization in large fragments of cloned genomic DNA (exon mapping). Normalization makes feasible the gridding of cDNA libraries on filters at high density by reducing the number of clones to be arrayed (gridding 10^7 clones for $1 \times$ coverage of a non-normalized library is not a

feasible task). Finally, by increasing the frequency of occurrence of rare cDNA clones while decreasing simultaneously the percentage of abundant cDNAs, normalization can expedite significantly the development of expressed sequence databases by random sequencing of cDNAs.

Although cDNA library normalization could be achieved by saturation hybridization to genomic DNA (6), this approach is impractical, since it would be extremely difficult to provide saturating amounts of the rarer cDNA species to the hybridization reaction. The alternative is the use of reassociation kinetics: assuming that cDNA reannealing follows second-order kinetics, rarer species will anneal less rapidly and the remaining single-stranded fraction of cDNA will become progressively normalized during the course of the reaction (6–8). As we report here, we have used this kinetic principle to develop a method for normalization of a directionally cloned cDNA library that has significant advantages over two previously reported similar procedures (refs. 7 and 8; see *Results and Discussion*).

MATERIALS AND METHODS

cDNA Library Construction. Poly(A)⁺ RNA isolated from the entire brain of a female infant (72 days old), who died in consequence of spinal muscular atrophy, was used for construction of a cDNA library (IB) as described (9, 10). As a primer for first-strand cDNA synthesis, we used the oligonucleotide 5'-AACTGGAAGAATTCGCGGCCGCGAG-GAAT₁₈-3', which contains a *Not* I site (underlined). After ligation to *Hind*III adaptors, the cDNAs were digested with *Not* I and cloned directionally into the *Hind*III and *Not* I sites of a phagemid vector (L-BA) constructed by modifying pEMBL-9(+) (11). L-BA carries an ampicillin-resistance gene, plasmid and filamentous phage (f1) origins of replication, and cloning sites (5' *Hind*III–*Bam*HI–*Not* I–*Eco*RI 3'). Superinfection of bacteria with the helper phage M13K07 (12) converts duplex plasmids into single-stranded DNA circles containing message-like strands of the cDNA inserts.

Preparation of Single-Stranded Library DNA. Plasmid DNA from the IB library was electroporated into *Escherichia coli* DH5 α F' bacteria, and the culture was grown under ampicillin selection at 37°C to an OD₆₀₀ of 0.2, superinfected with a 20-fold excess of the helper phage M13K07, and harvested after 4 hr for preparation of single-stranded plasmids, as described (12). To eliminate contaminating double-stranded, replicative form (RF) DNA, 20 μ g of the preparation was digested with *Pvu*II (which cleaves only duplex DNA molecules), extracted with phenol/chloroform, diluted by addition of 2 ml of loading buffer (0.12 M sodium phosphate buffer, pH 6.8/10 mM EDTA/1% SDS), and purified by hydroxyapatite (HAP) chromatography at 60°C, using a column preequilibrated with the same buffer (1-ml bed volume; 0.4 g of HAP). After a 6-ml wash with loading buffer,

Abbreviation: HAP, hydroxyapatite.

The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact.

this volume was combined with the flow through fraction, and the sample was extracted twice with water-saturated 2-butanol, once with dry 2-butanol, and once with water-saturated ether (3 volumes per extraction). The sample was desalted by passage through a Nensorb column (DuPont/NEN) according to the manufacturer's specifications, concentrated by ethanol precipitation, and electrophoresed in a low-melting agarose gel to remove helper phage DNA and any residual tRNA contaminant or oligoribonucleotides (breakdown products from the RNase A digestion used during purification). The region of the gel containing the single-stranded library was excised and, after β -agarase (New England Biolabs) digestion, the DNA was purified and ethanol-precipitated.

cDNA Library Normalization. The IB cDNA library was normalized (see Fig. 1) in two consecutive rounds to derive the normalized libraries ¹NIB and ²NIB, by using the following procedure. To synthesize a partial second strand of about 200 nt by limited extension, 9 pmol of the oligonucleotide primer 5'-GGCCGCAGGAAT_{15-3'} was added to 4.5 pmol of single-stranded IB library DNA in a 150- μ l reaction mixture containing 30 mM Tris-HCl (pH 7.5); 50 mM NaCl; 15 mM MgCl₂; 1 mM dithiothreitol; 0.1 mM dNTPs; 2.5 mM ddATP, ddCTP, and ddGTP; and a trace of [α -³²P]dCTP. The mixture was incubated for 5 min at 60°C and for 15 min at 50°C, the temperature was lowered to 37°C, 75 units of Klenow DNA polymerase (United States Biochemical) was added, and the incubation was continued for 30 min. The reaction was terminated by addition of EDTA (20 mM), extracted with phenol/chloroform, diluted with 2 ml of HAP loading buffer containing 50 μ g of sonicated and denatured salmon sperm DNA carrier, and chromatographed on HAP, as described above. After washing, the partial duplex circles bound to HAP were eluted from the column with 6 ml of 0.4 M phosphate buffer, pH 6.8/10 mM EDTA/1% SDS. The concentration of phosphate in the eluate was lowered to 0.12 M by addition of 14 ml of water containing 50 μ g of DNA carrier, and the chromatographic step was repeated. The final eluate was extracted and desalted as described above and the DNA was ethanol-precipitated. The pellet (112 ng) was dissolved in 2.5 μ l of formamide and the sample was heated for 3 min at 80°C under a drop of mineral oil to dissociate the DNA strands. For an annealing reaction, the volume was brought to 5 μ l by adding 0.5 μ l of 0.1 M Tris-HCl, (pH 7.5) containing 0.1 M EDTA, 0.5 μ l of 5 M NaCl, 1 μ l (5 μ g) of (dT)₂₅₋₃₀, and 0.5 μ l (0.5 μ g) of the extension primer. The last two ingredients were added to block stretches of adenine residues [representing the initial poly(A) tails] and regions complementary to the oligonucleotide on the single-stranded DNA circles. The annealing mixture was incubated at 42°C, and a 0.5- μ l aliquot was withdrawn at 13 hr (calculated C_{0t} , 5.5). The unhybridized single-stranded circles (normalized library) were separated from the reassociated partial duplexes by HAP chromatography and then recovered from the flow through fraction as described above. Since we, and others (13), have observed that the electroporation efficiency of partially repaired circular molecules is increased by about 100-fold in comparison with single-stranded circles, the normalized cDNA circles were converted to partial duplexes by primer extension using random hexamers and T7 DNA polymerase (Sequenase version II; United States Biochemical), in a 10–20 μ l reaction mixture containing 1 mM dNTPs. After addition of EDTA to 20 mM, phenol extraction, and ethanol precipitation, the cDNAs were dissolved in 10 mM Tris-HCl, pH 7.5/1 mM EDTA, and electroporated into competent bacteria (DH10B; GIBCO/BRL). To determine the number of transformants, 1 hr after the electroporation a 10- μ l aliquot of the culture was plated on an LB agar plate containing 75 μ g/ml ampicillin (extrapolation from these data indicated that a normalized library of 2.5×10^6 colonies was

obtained). Supercoiled plasmid DNA was then prepared (¹NIB library) with a Qiagen plasmid kit (Qiagen, Chatsworth, CA). The same protocol was used for a second round of normalization (calculated C_{0t} , 2.5) to derive the ²NIB library (1.3×10^7 transformants) from a preparation of ¹NIB single-stranded circles, except that the HAP purification step after primer extension to synthesize short complementary strands was omitted.

Colony Hybridization. For screening, colonies were grown on duplicate nylon filters (GeneScreenPlus; DuPont/NEN) that were processed as described (14) and hybridized at 42°C in 50% formamide/5 \times Denhardt's solution/0.75 M NaCl/0.15 M Tris-HCl, pH 7.5/0.1 M sodium phosphate/0.1% sodium pyrophosphate/2% SDS containing sheared and denatured salmon sperm DNA at 100 μ g/ml. Radioactive probes were prepared by random primed synthesis (15, 16) using the Prime-it II kit (Stratagene).

DNA Sequencing. Double-stranded plasmid DNA templates were prepared by using the Wizard Minipreps DNA purification system (Promega) and sequenced from both ends by using the universal forward and reverse M13 fluorescent primers. Reactions were assembled on a Biomek 1000 workstation (Beckman) and then transferred to a thermocycler (Perkin-Elmer/Cetus) for cycle sequencing. Reaction products were analyzed on an automated 370A DNA sequencer (Applied Biosystems). Nucleic acid and protein database searches were performed at the National Center for Biotechnology Information server using the BLAST algorithm (17).

RESULTS AND DISCUSSION

Experimental Strategy. To develop a normalization procedure, shown schematically in Fig. 1, and at the same time




FIG. 1. Diagram of the normalization procedure. Single-stranded circles of a library of directionally cloned cDNAs are primer extended under controlled conditions to generate complementary strands of about 200 ± 20 nt, and the resulting partial duplexes are purified from unprimed circles by HAP chromatography. Bound DNA is melted and reannealed to a relatively low C_{0t} (see text). The remaining single-stranded circles (normalized library) are isolated by HAP chromatography, converted into partial duplexes by random priming, and electroporated into bacteria for amplification.

increase the utility of the normalized model cDNA library, we first constructed a high-quality brain cDNA library (IB) that has the following features (10): the average size of a cDNA insert is 1.7 kb, often providing coding-region information by sequencing from the 5' end; the length of the segment representing the mRNA poly(A) tail is short, allowing an increase in the output of useful sequencing information from the 3' end; the frequency of nonrecombinant clones is extremely low (0.1%); and chimeric cDNAs have not been encountered, after single-pass sequencing of >2000 clones (10, 18). However, the latter analysis also demonstrated that 13% of the clones in the IB library lacked poly(A) tails and were presumably derived from aberrant priming.

To preserve the length of the cDNAs, avoid differential loss of sequences, and alleviate a need for subcloning steps after normalization, we excluded from our protocol the use of PCR and chose directional cloning into a phagemid vector. Such vectors have been previously used advantageously for cDNA library subtractions (13), although normalization was not attempted. This cloning regime readily provides single strands that can be used both for annealing and for direct propagation in bacteria. In control experiments (data not shown), we assessed the frequency of occurrence of abundant cDNAs (encoding α - and β -tubulin, elongation factor 1 α , and myelin basic protein) and demonstrated that, at least by this criterion, the representation of clones in the starting library remained unchanged after conversion into single-stranded circles. We also note that electrophoretic purification of the circles prior to use is necessary, to remove contaminating oligonucleotides (see *Materials and Methods*), whose presence would result in undesirable internal priming events during the first step of our protocol.

In contrast with our scheme, two other PCR-based normalization methods (7, 8) necessitate the use of subcloning steps. In one of these approaches (7), sheared cDNAs (0.2–0.4 kb) were ligated to a linker–primer, amplified by PCR, normalized kinetically, reamplified, and finally cloned directionally in such a way that only 3'-terminal sequences (almost exclusively 3' noncoding regions) were purposely preserved. The steps of the second scheme (8) were similar, except that the process started from cloned, randomly primed, and relatively short cDNAs, initially selected to minimize length-dependent differential PCR amplification. Thus, both coding and noncoding regions were represented in the final normalized library, but in pieces.

While maintaining length and representation of mRNA regions, our protocol (Fig. 1) also addresses successfully the problem recognized in the first of the alternative approaches (7). It was considered that the 3' noncoding region is almost always unique to the transcript that it represents and is expected, therefore, to anneal only to its complement. In contrast, cross-hybridization of coding regions belonging to unequally represented members of oligo- or multigene families could result in the elimination of rarer members from the population during the normalization process. This possibility is precluded in our method, which begins with the synthesis, from the 3' end of the cDNA, of a short complementary strand on the circular single-stranded cDNA template under controlled conditions, calibrated to yield strands with a narrow size distribution (200 ± 20 nt). Since the average length of 3' noncoding regions in brain mRNAs is 750 nt (19), the vast majority of synthesized complementary strands participating in the annealing reaction should be devoid of coding region sequences. However, after this partial extension step, purification of the products by HAP chromatog-




FIG. 2. Comparison of the frequencies of cDNA probes in the original (IB) and two normalized (1NIB and 2NIB) libraries. The indicated percentages of 28 cDNA sequences in the three libraries, tabulated in order of decreasing frequency in the IB library, are shown in the form of a histogram to visualize normalization. Frequencies were calculated from the number of positive colonies after hybridization of duplicate filters containing 500–180,000 colonies from each of the three cDNA libraries with the following 28 probes: 1, elongation factor 1 α ; 2, α -tubulin; 3, β -tubulin; 4, myelin basic protein; 5, aldolase; 6, 89-kDa heat shock protein; 7, γ -actin; 8, secretogranin; 9, microtubule-associated protein; 11, vimentin; 13, a cDNA randomly picked from the 1NIB library similar to a mouse cysteine-rich intestinal protein (1NIB-2, GenBank accession nos. T09996 and T09997); 19, a cDNA isolated from the 1NIB library homologous to the human endogenous retrovirus RTVLH2 (cDNA-20, accession nos. L13822 and L13823); 20, histone H2b.1; 23, a cDNA randomly picked from the 1NIB library encoding the human polyposis (DPI gene) mRNA (1NIB-227, accession nos. T10266 and T10267); 27, a cDNA randomly picked from the 1NIB library related to the human endogenous retrovirus ERV9 gene (1NIB-114, accession nos. T10086 and T10087); the remaining brain cDNAs are novel, and except for nos. 10, 18, 21, and 25, they were randomly picked from the 1NIB library.

raphy is necessary to eliminate single strands of the IB library lacking poly(A) tails that cannot participate in primed synthesis. We repeat the chromatographic step to reduce the background to negligible levels, since after the first passage through the HAP column about 0.1% of pure single strands bind nonspecifically. However, during the second round of normalization to derive the ²NIB library, we omitted this step since we showed that 187 clones, which were picked randomly and sequenced from the ¹NIB library (see below), all contained 3' poly(A) stretches. The remaining steps of our procedure entail melting and reannealing of the partial duplexes, followed by purification of unreassociated circles (normalized library) by HAP chromatography and electroporation into bacteria (Fig. 1).

Characterization of Normalized cDNA Libraries. To evaluate the extent of normalization achieved with our method, we compared the IB, ¹NIB, and ²NIB libraries by colony hybridization. For this analysis, we used 28 cDNA probes chosen to represent various frequencies of occurrence within a wide range (at least 4 orders of magnitude: 4.6% to <0.0006%) in the IB library (Fig. 2). However, an additional comparison of these results with independent theoretical estimates was necessary, to provide a further assessment of the degree of normalization, especially because the ¹NIB library was derived after incubation to a relatively low *C*₀*t* (5.5) during the reannealing step of our procedure. When relatively high *C*₀*t* values were used in our initial attempts to normalize the IB library, we obtained unsatisfactory results (high background) that we attribute to technical problems inherent to the procedure. Nevertheless, a reevaluation of brain cDNA hybridization data (ref. 20; see Table 1) suggests that a relatively low *C*₀*t* would suffice for our purpose, to bring the frequency of each library clone within a narrow range.

For our calculations (Table 1), which should be regarded as rough but indicative estimates, we used a set of reliable hybridization data that are available only for mouse brain mRNAs (20), assuming that these measurements should not differ significantly among mammals (in all cases examined,

including humans, the average amount of RNA per brain cell and the number of cells per gram of tissue are practically the same; see, e.g., refs. 29 and 30). These calculations show that at *C*₀*t* 5.5, of the three kinetic classes of mRNAs, the most abundant species are drastically diminished, while all frequencies are brought within the range of 1 order of magnitude (Table 1, compare columns b and h and columns f and i). Our experimental results (Fig. 2) show that the same range was achieved after a single round of normalization at this *C*₀*t* (5.5). Thus, for all practical purposes, a single cycle is probably sufficient. Secondary normalization (calculated *C*₀*t* = 2.5) to derive the ²NIB library, although it did not result in a dramatic improvement, preserved the range of frequencies, while making the differences among individual sequences narrower overall (Fig. 2). Eleven of the 28 probes used in this analysis were derived from clones that were randomly picked from the ¹NIB library. The overall frequency fold variation was reduced from >7667 (4.6/<0.0006) in the IB library to 133 (0.4/0.003) and 26 (0.1/0.01) in the ¹NIB and ²NIB libraries, respectively. However, some unexplained anomalies were also observed for a small minority of clones, whose already reduced frequencies in the ¹NIB library were somewhat increased in the ²NIB library (Fig. 2).

To provide a further indication that normalization was successful, we sequenced from both ends 187 cDNA clones that were randomly picked from the ¹NIB library (GenBank accession numbers T09994-T10011 and T10014-T10369). With the exception of 4 clones, which carried sequences corresponding to human mitochondrial 16S rRNA, all other cDNAs of this pool were unique, in agreement with the expectation for a normalized library. To further investigate the effect of the normalization procedure on the subset of mitochondrial 16S rRNA clones (1.4%, 1%, and 0.4% in the IB, ¹NIB and ²NIB libraries, respectively), we compared the sequences of a number of 16S rRNA clones isolated from both the IB and ¹NIB libraries (kindly provided by M. Adams, Institute for Genomic Research and J. Sikela, University of Colorado). This analysis (data not shown) revealed that the 16S rRNA clones isolated from ¹NIB did not correspond to

Table 1. Estimates of frequencies of brain mRNAs

Component ^a	% ^b	<i>k</i> _{pt0} (pure) ^c	Complexity, ^d kb	No. of RNA species ^e	Frequency per species, ^f %	<i>k</i> _{so} ^g	Component at <i>C</i> ₀ <i>t</i> 5.5, ^h %	Final frequency per species, ⁱ %
I	16	10	96	36	0.44	6.15	0.7	0.02
II	46	0.165	5,800	2,150	0.02	0.10	44.2	0.02
III	38	0.0079	122,000	45,000	0.0008	0.0048	55.1	0.0012

^aThe experimental data of pseudo-first-order hybridization kinetics of cDNA tracer, which was synthesized from mouse brain poly(A)⁺ polysomal mRNA and driven by its template (20), were solved by computer (unconstrained fit) into three kinetic components, using the EXCESS function of a least-squares curve-fitting program (21).

^bThe fraction of total occupied by each of the components is shown, after a minor correction (at completion, practically all of the tracer had reacted). These numbers (and all other numbers) in the table have been rounded.

^cThe computer-calculated pseudo-first-order hybridization rate constant (*k*_{pt0}; M⁻¹sec⁻¹) for each component was divided by each of the values in column b, to derive *k*_{pt0} (pure).

^dThe complexity (i.e., length of unique sequence) was calculated by considering the data from a calibration kinetic standard: cDNA synthesized from encephalomyocarditis virus RNA (complexity, 9.7 kb) that was driven by its template [*k*_{pt0} (pure), 99]. Thus, each of the values in column d is the ratio (99 × 9.7)/*k*_{pt0} (pure). The complexity calculated for the rarest component (III) matches closely the values obtained from additional kinetic experiments using cDNA enriched for infrequent sequences (22, 23) and also the data of saturation experiments with single-copy genomic DNA tracer (24, 25).

^eThe number of different RNA species in each component was estimated from their complexities by assuming that the average size of brain mRNA is 2.7 kb (26). A conjecture (26) that rare brain mRNAs are longer than this value (hypothetically 5 kb on average) has not been supported by hard evidence.

^fThe initial average frequency of an individual mRNA species of each component in the entire population of mRNA molecules is the ratio of values in column b to those in column e.

^gTo assess the behavior of these kinetic components under the annealing conditions that we used for normalization (*C*₀*t*, 5.5; length of complementary sequence in annealing strands, 0.2 kb), we first calculated the second-order reassociation rate constant (*k*_{so}; M⁻²sec⁻¹) for each component. For this calculation, we considered that the *k*_{so} of a single and pure kinetic component with a complexity of 1 kb reacting at a fragment length of 0.2 kb is 590 (27, 28). Thus each *k*_{so} value is 590 divided by the complexity in column d.

^hTo determine the percentage of the leftover of each component in the population at *C*₀*t* 5.5, we first used the *k*_{so} values in column g to calculate the fraction remaining single-stranded, according to the equation *C*/*C*₀ = 1/(1 + *k*_{so}*t*) and then normalized the derived values to a total of 100%.

ⁱThe final average frequency of an individual mRNA species of each component is the ratio of values in column h to those in column e.

the predominant 16S rRNA species present in the IB library. Interestingly, in 17 of 19 16S rRNA clones sequenced from the IB library, the position of the A tract was the same as that present in the mature 16S rRNA. In contrast, all 8 clones sequenced from the ¹NIB library represented truncated versions of the 16S rRNA, in which different lengths of the 3' terminal sequence were absent. Such truncated clones are under represented in the IB library (2 of 19). Therefore, their frequency was increased by normalization, as expected, while the 16S rRNA clones of the most prevalent form were reduced. It is likely that the shorter clones represent bona fide copies of naturally occurring truncated 16S rRNA molecules (ref. 31–33; to be discussed elsewhere).

Database searches (both BLASTN and BLASTX; ref. 17) revealed that of the 183 cDNAs examined, 152 (83%) were unknown (no hits), 15 (8.2%) corresponded to known human sequences, 5 (2.7%) were novel but related to known human sequences, 4 (2.2%) were homologous to mammalian sequences, and 7 (3.8%) were homologous to known sequences from various nonmammalian organisms.

In contrast to these results, when 1633 randomly picked clones from the non-normalized IB library were sequenced mostly (88%) from the 5' end, the percentage of unknown sequences was significantly lower than in our case (63%), while about 30% of the clones were sequenced twice or more (up to 50) times (10). Similar results were obtained by sequencing 493 random IB clones exclusively from the 3' end (18). Of the initially abundant cDNAs, which were sequenced multiple times in both of these studies, those encoding elongation factor 1 α , α -tubulin, β -tubulin, myelin basic protein, and γ -actin (corresponding to our probes 1–4 and 7; Fig. 2) were absent from the pool of 187 clones that we examined. Moreover, only 15 of the unique 183 clones that we sequenced from the ¹NIB library (8%) had been previously identified in the collection of the sequenced 1633 IB clones.

Eighteen of the unknown cDNAs that we sequenced (10% of the total clones) carried *Alu* repetitive elements (6 at the 5' end; 11 at the 3' end; and 1 at both ends). Thus, as previously observed (8), the frequency of cDNAs containing *Alu* repeats is not reduced by normalization. This phenomenon can be attributed to sequence heterogeneity among *Alu* family members, which are able to form imperfect hybrids that probably cannot bind to HAP. However, this is not a disadvantageous property, since it prevents elimination of rare *Alu*-carrying cDNAs from the population.

To assess whether the normalization procedure had skewed the distribution of lengths favoring shorter cDNA clones, Southern blots of released inserts from the IB, ¹NIB, and ²NIB plasmids were hybridized with several of the cDNA probes used in Fig. 2 individually. The results (not shown) demonstrated that the intensity of hybridization signals varied as expected, but the size of each hybridizing fragment remained the same.

Note. Sasaki *et al.* (34) have described an alternative normalization procedure, in which a cDNA library was constructed following depletion of abundant mRNA species by sequential cycles of hybridization to matrix-bound cDNA. However, this procedure does not seem to be more advantageous than ours, while its actual practical potential remains to be assessed, as the putative normalized library was not adequately characterized.

We thank Greg Lennon (Lawrence Livermore National Laboratories) for arraying 40,000 clones of the ¹NIB library and making it available to other investigators; M. Adams and J. Sikela for kindly providing sequences of 16S rRNA clones isolated from the IB and ¹NIB libraries, respectively; M. Adams for making a set of 1633 sequences available to us prior to publication; and Rachel Yarnolinsky for help with the figures. This work was supported by Grant

FG02-91ER61233 from the U.S. Department of Energy and by Grants 1R55HD28422 and BRSG 2 S07 RR05395-30 from the National Institutes of Health to M.B.S.; by Grants HG00362, HG00424, and HG00861 from the National Institutes of Health to A.E.; and by a generous gift from the W. M. Keck Foundation.

- Davidson, E. H. & Britten, R. J. (1979) *Science* 204, 1052–1059.
- Bishop, J. O., Morton, J. G., Rosbash, M. & Richardson, M. (1974) *Nature (London)* 250, 199–204.
- Hahn, W. E. & Owens, G. P. (1988) in *The Molecular Biology of Neurological Disease*, eds. Rosenberg, R. N. & Harding, A. E. (Butterworths, London), pp. 22–34.
- Kaplan, B. & Finch, C. (1982) in *Molecular Approaches to Neurobiology*, ed. Brown, I. (Academic, New York), pp. 71–98.
- Snider, B. J. & Morrison-Bogorad, M. (1992) *Brain Res. Rev.* 17, 263–282.
- Weissman, S. M. (1987) *Mol. Biol. Med.* 4, 133–143.
- Ko, M. S. H. (1990) *Nucleic Acids Res.* 18, 5705–5711.
- Patanjali, S. R., Parimoo, S. & Weissman, S. M. (1991) *Proc. Natl. Acad. Sci. USA* 88, 1943–1947.
- Soares, M. B. (1994) in *Automated DNA Sequencing and Analysis Techniques*, ed. Venter, J. C. (Academic, London), pp. 110–114.
- Adams, M. D., Soares, M. B., Kerlavage, A. R., Fields, C. & Venter, J. C. (1993) *Nat. Genet.* 4, 373–380.
- Dente, L., Cesareni, G. & Cortese, R. (1983) *Nucleic Acids Res.* 11, 1645–1655.
- Vieira, J. & Messing, J. (1987) *Methods Enzymol.* 153, 3–11.
- Rubenstein, J. L. R., Brice, A. E. J., Ciaranello, R. D., Denney, D., Porteus, M. H. & Usdin, T. B. (1990) *Nucleic Acids Res.* 18, 4833–4842.
- Grunstein, M. & Hogness, D. (1975) *Proc. Natl. Acad. Sci. USA* 72, 3961–3965.
- Feinberg, A. P. & Vogelstein, B. (1983) *Anal. Biochem.* 132, 6–13.
- Feinberg, A. P. & Vogelstein, B. (1984) *Anal. Biochem.* 137, 266–267.
- Altschul, S. F., Gish, W., Miller, W., Myers, E. W. & Lipman, D. J. (1990) *J. Mol. Biol.* 215, 403–410.
- Khan, A. S., Wilcox, A. S., Polymeropoulos, M. H., Hopkins, J. A., Stevens, T. J., Robinson, M., Orpana, A. K. & Sikela, J. M. (1992) *Nat. Genet.* 2, 180–185.
- Hawkins, J. D. (1988) *Nucleic Acids Res.* 16, 9893–9908.
- Hahn, W. E., Van Ness, J. & Maxwell, I. H. (1978) *Proc. Natl. Acad. Sci. USA* 75, 5544–5547.
- Pearson, W. R., Davidson, E. H. & Britten, R. J. (1977) *Nucleic Acids Res.* 4, 1727–1737.
- Van Ness, J. & Hahn, W. E. (1982) *Nucleic Acids Res.* 10, 8061–8077.
- Chaudhary, N. & Hahn, W. E. (1983) *Science* 220, 924–928.
- Bantle, J. A. & Hahn, W. E. (1976) *Cell* 8, 139–150.
- Grouse, L. D., Schrier, B. K., Bennett, E. L., Rosenzweig, M. R. & Nelson, P. G. (1978) *J. Neurochem.* 30, 191–203.
- Milner, R. J. & Sutcliffe, J. G. (1983) *Nucleic Acids Res.* 11, 5497–5520.
- Galau, G. A., Britten, R. J. & Davidson, E. H. (1977) *Proc. Natl. Acad. Sci. USA* 74, 1020–1023.
- Welsh, J., Liu, J.-P. & Efstratiadis, A. (1990) *Genet. Anal. Technol. Appl.* 7, 5–17.
- Mandel, P., Rein, H., Harth-Edel, S. & Mardell, R. (1964) in *Comparative Neurochemistry*, ed. Richter, D. (Macmillan, New York), pp. 149–163.
- Winick, M. (1968) *Pediatr. Res.* 2, 352–355.
- Mazo, A. M., Minchenko, A. G., Avdonina, T. A., Gause, G. G. & Pusyriov, A. T. (1983) *Mol. Biol. Rep.* 9, 155–161.
- Baserga, S. J., Linnenbach, A. J., Malcolm, S., Ghosh, P., Malcolm, A. D. B., Takeshita, K., Forget, B. G. & Benz, E. J., Jr. (1985) *Gene* 35, 305–312.
- Christianson, T. W. & Clayton, D. A. (1988) *Mol. Cell. Biol.* 8, 4502–4509.
- Sasaki, Y. F., Ayusawa, D. & Oishi, M. (1994) *Nucleic Acids Res.* 22, 987–992.

2

Molecular Cloning

A LABORATORY MANUAL

BEST AVAILABLE COPY

Sambrook Fritsch Maniatis

Abundant mRNAs

Initially, cDNA cloning was used to obtain copies of abundant mRNAs such as those encoding globin, immunoglobulins, and ovalbumin. In these cases, the RNA species of interest constitutes as much as 50–90% of the total poly(A)⁺ cytoplasmic RNA isolated from specific types of differentiated cells. Consequently, no further purification of the particular mRNA is required before double-stranded cDNA is synthesized and cloned. The desired cDNA clones can easily be identified by nucleic acid hybridization. The probes consist either of ³²P-labeled single-stranded cDNA synthesized in vitro by reverse transcriptase, using as the template mRNA preparations that are rich in the sequences of interest, or of mRNA that has been partially fragmented by limited alkaline hydrolysis and end-labeled by phosphorylation. As a good approximation, the mRNA sequences of interest will be represented in both the probe and the cloned double-stranded cDNAs in proportion to their abundances in the original preparation of mRNA. In cases such as globin, immunoglobulins, and ovalbumin, the chances are high that any colony hybridizing strongly to the probe will contain the desired DNA sequences. Although used extensively in the early days of cDNA cloning, this method no longer finds wide application, since few systems remain in which interesting uncloned mRNAs represent a sufficiently high proportion of the starting population.

Low-abundance mRNAs

mRNAs that represent less than 0.5% of the total mRNA population of the cell are classified as “low-abundance” or “rare” mRNAs. The isolation of cDNA clones for mRNAs of this type presents two major problems: (1) construction of a cDNA library whose size is sufficient to ensure that the clone of interest has a good chance of being represented and (2) identification and isolation of the clone(s) of interest.

Methods of Enrichment

A typical mammalian cell contains between 10,000 and 30,000 different mRNA sequences (Davidson 1976). Not all of these sequences are represented equally in the steady-state population of mRNA molecules. Instead, the proportional representation of each sequence depends on its rate of synthesis and half-life: Genes that are actively transcribed into stable mRNAs will make a greater contribution to the pool of mRNA molecules than genes that are transcribed sluggishly into less stable mRNAs. Williams (1981) has determined the number of clones necessary to construct a complete cDNA library from a human fibroblast cell that contains approximately 12,000 different mRNA sequences. Low-abundance mRNAs (<14 copies/cell) constitute approximately 30% of the mRNA, and there are about 11,000 different mRNAs belonging to this class. The minimum number of cDNA clones required to obtain a complete representation of mRNAs of this class is therefore $11,000/0.30 \approx 37,000$. Of course, because of sampling variation and/or preferential cloning of certain sequences, a much larger number of recombinants must be obtained to increase the chances that any given clone

will be represented in the library. The number of clones required to achieve a given probability that a low-abundance mRNA will be present in a cDNA library is

$$N = \frac{\ln(1 - P)}{\ln(1 - 1/n)}$$

where N = the number of clones required, P = the probability desired (usually 0.99), and $1/n$ = the fractional proportion of the total mRNA that is represented by a single type of rare mRNA.

Therefore, to achieve a 99% probability of obtaining a cDNA clone of an mRNA present in human fibroblasts at a frequency of approximately 14 molecules/cell:

$$P = 0.99$$

$$1/n = 1/37,000$$

$$N = 170,000$$

Unfortunately, many mRNAs of interest are present at even lower levels (1 molecule/cell is not unusual [Toole et al. 1984; Wood et al. 1984]). Furthermore, it is often necessary to clone cDNAs from populations of mRNAs isolated from tissues that consist of several cell types. In such cases, the frequency at which the sequences of interest are represented in the initial preparation of mRNA may be reduced still further, and it then becomes necessary to construct and screen libraries that contain several million independent cDNA clones. During the last few years, the efficiency with which cDNA can be synthesized and cloned has increased to the point where cDNA libraries of this size can be generated routinely from 10 μ g or less of poly(A)⁺ mRNA. In principle, there is no a priori reason why even the most difficult cDNA clones—those corresponding to a very rare mRNA of large size—cannot be identified in such comprehensive libraries. However, screening large numbers of cDNA clones is both tedious and expensive. Methods have therefore been devised to enrich either the starting population of mRNA molecules or double-stranded cDNA synthesized from it for sequences of interest. Enrichment allows the size of the cDNA library to be reduced and decreases the cost and labor involved in screening for the desired cDNA clones.

It is difficult to offer specific guidelines regarding the circumstances that require enrichment procedures. As a rule of thumb, fractionation of mRNA is probably unnecessary if the cDNA of interest is expected to be present at a frequency ≥ 1 in 10^6 in a library of cDNA clones synthesized from unfractionated mRNA. Enrichment becomes more attractive as the number of clones to be screened increases above one million. When designing a scheme to clone a specific cDNA, it is therefore important to know the approximate frequency with which the mRNA of interest occurs in the bulk, unfractionated population of mRNA molecules. In the absence of nucleic acid probes, an indirect method must be used to measure this frequency. Usually, the mRNA preparation is translated in a cell-free system and the total amount of radioactivity incorporated into protein is measured. The polypeptide of interest is then immunoprecipitated and identified by electrophoresis through an SDS-polyacrylamide gel. The amount of radioactivity in the excised band is then measured and used to calculate the proportion of the total counts that have been incorporated into the protein of interest. This proportion is taken

as a measure of the frequency with which the mRNA occurs in the bulk population. Despite its obvious limitations, this method usually yields estimates that are sufficiently reliable to allow rational schemes for cDNA cloning to be devised.

Clearly, fractionation works best for mRNAs that are much larger or smaller in size than the bulk mRNA of the cell. The modal size of the mRNA population extracted from most types of mammalian cells is approximately 1.8 kb, and mRNAs smaller in size than 700 bases or larger than 4 kb can be enriched at least tenfold by a single round of density gradient centrifugation carried out under denaturing conditions. However, it is important to remember that it is not possible to predict with certainty the size of an mRNA from the size of a protein for which it codes. There is considerable variation in the sizes of the untranslated regions of mRNAs (particularly the 3' untranslated regions); many proteins purified from cells are cleavage products of larger precursors and many undergo extensive posttranslational modification. However, the size of the unmodified polypeptide chain provides a minimal estimate of the size of the mRNA: 10,000 daltons of an average polypeptide is encoded by approximately 280 bases of mRNA.

FRACTIONATION OF mRNA BY SIZE

The simplest method to enrich preparations of mRNA for sequences of interest is to fractionate them according to size. Electrophoresis through agarose gels gives the best separation of molecules of mRNA of different sizes, but the recovery of RNA from gel slices is generally poor. Sedimentation through sucrose gradients formed in nondenaturing solvents results in good recovery, but the presence of secondary structure in the RNA often confounds effective fractionation. The method of choice, therefore, is sucrose gradient centrifugation in the presence of an agent, such as methylmercuric hydroxide, that denatures secondary structure in RNA (Schweinfest et al. 1982) (for experimental protocol, see Chapter 7, page 7.35). Each fraction is then assayed for the presence of the mRNA that codes for the relevant polypeptide. Typically, an aliquot of the RNA in each fraction is translated in a cell-free system and the resulting polypeptides are analyzed by immunoprecipitation and electrophoresis through polyacrylamide gels. Alternatively, aliquots are injected into *Xenopus* oocytes (for review, see Melton 1987) and the resulting products are assayed either for biological activity or by immunoprecipitation and gel electrophoresis. The fraction that directs the synthesis of the greatest amount of the polypeptide product is then used as the starting material for construction of a cDNA library.

FRACTIONATION OF cDNA

Until a few years ago, fractionation of mRNA was the method of choice for cloning of mRNAs that code for large proteins (e.g., rat skeletal muscle tropomyosin [Medford et al. 1980] and chick creatine kinase [Schweinfest et al. 1982]). However, as methods for the synthesis of cDNA have improved, fractionation of double-stranded cDNA has become a more practical alternative, and there are now many examples of extremely large cDNAs that have been cloned by fractionating cDNA rather than the mRNA from which it was

copied (e.g., human factor VIII:C [Toole et al. 1984; Wood et al. 1984] and human sucrase-isomaltase [Hunziker et al. 1986]). Fractionation of cDNA has major advantages: DNA is less susceptible than mRNA to degradation by contaminating nucleases; it can be fractionated more accurately by electrophoresis through agarose gels; and, finally, since the fractionation can be carried out at a late stage during the cDNA cloning protocol, the chances of subsequent mishaps are reduced and the probability of obtaining a full-length clone of cDNA is increased. Fractionation is usually carried out after all of the enzymatic reactions involved in cDNA synthesis have been completed and just before the cDNA is inserted into a vector. In the detailed protocol described later in this chapter, fractionation is carried out after synthetic linkers, added to the termini of double-stranded cDNA, have been digested with a restriction enzyme. The cDNA is fractionated by electrophoresis through an agarose gel of appropriate porosity, using markers whose sizes are known accurately. Molecules of the desired size are recovered and inserted into the vector.

IMMUNOLOGICAL PURIFICATION OF POLYSOMES

An alternative method of enrichment involves the use of antibodies to purify polysomes that are synthesizing the polypeptide of interest. The technique described originally (Palacios et al. 1972; Schechter 1973), which involved the immunoprecipitation of polysomes, worked well for mRNAs encoding abundantly synthesized proteins such as albumin and immunoglobulin, although attempts to apply the method to mRNAs of lesser abundance were generally disappointing. However, the more recent use of immunoaffinity columns (Schutz et al. 1977) and protein A-Sepharose columns (Shapiro and Young 1981) has led to a resurgence of the technique. For example, Korman et al. (1982) used a monoclonal antibody directed against the heavy chain of the human HLA-DR histocompatibility antigen to bind polysomes synthesizing the nascent protein to protein A-Sepharose columns. The polysomes were then dissociated with EDTA and the mRNA isolated by oligo(dT) chromatography. The immunoaffinity-purified mRNA, which represented only 0.01–0.05% of the total mRNA, was used both to prepare cDNA probes and to construct cDNA clones. Using similar methods with polyclonal antisera, Kraus and Rosenberg (1982) obtained a 6300-fold purification of the mRNA that codes for rat liver cystathionine β -synthase and Russell et al. (1983) isolated cDNA clones for the bovine low-density-lipoprotein receptor, whose mRNA is present at approximately 80 copies per cell in bovine adrenal cells.

Although a powerful technique, immunoaffinity purification of polysomes cannot be applied universally. First, it clearly will not work unless a reliable source of material is available from which to isolate functional polysomes. This is not always possible, especially when the starting material is a tissue or organ that is not commonly available. Second, it has not yet been shown to work for mRNAs that are extremely rare (1 molecule/cell or less). Furthermore, the success of the method depends entirely on the specificity, avidity, and type of the particular antibody, and it is not always possible to translate the results obtained with one antibody directly to another. Finally, the method requires the use of relatively large quantities of antibody. Partly

because of these difficulties, immunoaffinity purification of polysomes has been superseded by development of cDNA cloning vectors (e.g., λ gt11 and λ gt18-23) that allow the direct isolation of cDNA clones that code for specific antigens. Whether or not the method is used extensively in the future will depend on improving its sensitivity to the point where it provides significant enrichment of polysomes carrying extremely rare mRNAs.